Emam Heba, Refaat Alaa, Jawaid Paras, Ur Rehman Mati, Li Peng, Zhao Qing-Li, Kondo Takashi
Department of Radiological Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Department of Cancer Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Oncol Lett. 2017 Jul;14(1):1035-1040. doi: 10.3892/ol.2017.6256. Epub 2017 May 26.
Bufadienolides are constituents of the traditional Chinese medicine Chan Su and are found in toad venom. Cardiovascular side-effects are one of the limiting factors towards developing bufadienolides as chemotherapeutic agents. Thus, in the present study, low doses of bufalin and cinobufotalin, prominent members of the bufadienolides, were investigated for their cytotoxic activity in combination with hyperthermia (HT) or radiation (Rad) therapy. In addition, the underlying mechanism involved was investigated. A DNA fragmentation assay, viability assay and microscopic observation were primarily used to assess the effect of low doses of the two drugs in human lymphoma U937 cells. Furthermore, the effects of these drugs on the mitochondrial membrane potential (MMP) and apoptotic-associated protein activation were investigated. HT/bufadienolide- and RT/bufadienolide-treated samples significantly increased the DNA fragmentation percentile and decreased the MMP, as well as increasing the apoptotic features observed microscopically within a relatively short time (6 h) after treatment. The two combinations affected the expression of important apoptotic markers, including caspase-3 and BH3 interacting domain death agonist. The findings of the current study confirm the additive effect of HT with this group of drugs, directing a novel therapeutic avenue for the clinical use of bufadienolides at lower doses with more restrained cardio toxic side-effects.
蟾毒配基是中药蟾酥的成分,存在于蟾蜍毒液中。心血管副作用是将蟾毒配基开发为化疗药物的限制因素之一。因此,在本研究中,研究了低剂量的蟾毒灵和华蟾酥毒基(蟾毒配基的主要成分)与热疗(HT)或放疗(Rad)联合使用时的细胞毒性活性。此外,还研究了其中涉及的潜在机制。主要使用DNA片段化分析、活力分析和显微镜观察来评估低剂量的这两种药物对人淋巴瘤U937细胞的影响。此外,还研究了这些药物对线粒体膜电位(MMP)和凋亡相关蛋白激活的影响。热疗/蟾毒配基和放疗/蟾毒配基处理的样本显著增加了DNA片段化百分比,降低了MMP,并在处理后相对较短的时间(6小时)内增加了显微镜下观察到的凋亡特征。这两种联合处理影响了重要凋亡标志物的表达,包括半胱天冬酶-3和BH3相互作用结构域死亡激动剂。本研究结果证实了热疗与这类药物的相加作用,为低剂量、心脏毒性副作用更可控的蟾毒配基临床应用指明了一条新的治疗途径。